X

Merck to Buy Schering-Plough in Latest Pharma Merger

Drug giant's purchase comes weeks after Pfizer-Wyeth merger
By Jason Farago,  Newser Staff
Posted Mar 9, 2009 6:34 AM CDT

(Newser) – Merck announced today that it will merge with fellow drugmaker Schering-Plough in a $41.1 billion cash-and-stock deal to enlarge its pipeline of new drugs in development, reports the Wall Street Journal. The two companies have already collaborated on cholesterol drug Zetia—whose sales plummeted after a study questioned its effectiveness. The merger comes 6 weeks after rival Pfizer announced its acquisition of Wyeth.

story continues below

The deal will see Schering-Plough shareholders acquire just over half a Merck share plus $10.50 in cash for each share they own. That works out to a 34% premium on Friday's closing price of Schering-Plough.
(Read more merger stories.)

We use cookies. By Clicking "OK" or any content on this site, you agree to allow cookies to be placed. Read more in our privacy policy.
Get the news faster.
Tap to install our app.
X